Peptides & the FDA review: your questions, answered

It wasn't on the July 2026 agenda. Analysts of the April 2026 action expect the remaining peptides to be reviewed at a later meeting (reported as early 2027); no official FDA notice had confirmed a date as of July 2026.^{1 2}

Yes - LL-37 is a natural human antimicrobial peptide. That doesn't make a manufactured, injected version approved or proven; it remains investigational.³

LL-37 is not an FDA-approved drug and has no cleared compounding pathway. It was removed from Category 2 in April 2026 but is not on the July 2026 agenda; a later review is expected.^{2 1}